1048346-74-2

Usage

Uses

Used in Pharmaceutical Research:
(S)-4-[(ethyl-phenyl-amino)-methyl]-4,5-dihydro-oxazol-2-ylamine is used as a compound in pharmaceutical research for its structural features and potential biological activity. The presence of various functional groups in its structure may allow it to interact with biological targets, making it a candidate for the development of new drugs or therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-4-[(ethyl-phenyl-amino)-methyl]-4,5-dihydro-oxazol-2-ylamine is used as a starting material or a building block for the synthesis of more complex molecules with specific therapeutic properties. Its unique structure may be exploited to design novel drugs targeting various diseases or medical conditions.
Used in Drug Delivery Systems:
(S)-4-[(ethyl-phenyl-amino)-methyl]-4,5-dihydro-oxazol-2-ylamine may also be used in the development of drug delivery systems, where its structural features could be utilized to enhance the solubility, stability, or targeted delivery of therapeutic agents. This application could improve the bioavailability and efficacy of drugs, leading to better treatment outcomes for patients.
Used in Chemical Synthesis:
As a complex organic molecule, (S)-4-[(ethyl-phenyl-amino)-methyl]-4,5-dihydro-oxazol-2-ylamine can be used in chemical synthesis to create a variety of derivatives with different properties and applications. These derivatives may find use in various industries, such as agriculture, materials science, or environmental science, depending on their specific characteristics.

Upstream product

• 1048350-62-4 (S)-2,2-dimethyl-4-phenylaminomethyloxazolidine-3-carboxylic acid tert-butyl ester 
• 62-53-3 aniline 
• 1048350-72-6 (S)-4-[(ethyl-phenyl-amino)methyl]-2,2-dimethyloxazolidine-3-carboxylic acid tert-butyl ester 
• 103-69-5 N-ethyl-N-phenylamine 
• 506-68-3 bromocyane 
• 1048350-75-9 (S)-2-amino-3-(ethyl-phenyl-amino)-propan-1-ol 

Relevant academic research and scientific papers

OXAZOLINE PSEUDODIMERS, PHARMACEUTICAL COMPOSITIONS AND THE USE THEREOF

The present disclosure is directed to oxazoline mono- and hetero-pseudodimer compounds, such as compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: These compounds are useful for treating pain. The present disclosure also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Formula (I) or (II) or a pharmaceutically acceptable salt or solvate thereof

Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 Agonists

2-Aminooxazolines were discovered as a novel structural class of TAAR1 ligands. Starting from a known adrenergic compound 1, structural modifications were made to obtain highly potent and selective TAAR1 ligands such as 12 (RO5166017), 18 (RO5256390), 36 (RO5203648), and 48 (RO5263397). These compounds exhibit drug-like physicochemical properties, have good oral bioavailability, and display in vivo activity in a variety of animal models relevant for psychiatric diseases and addiction.

Pharmaceutical combination

The present invention relates to a pharmaceutical combination for the treatment of schizophrenia and acute manic episodes associated with bipolar disorders, which comprises a compound which is active on a trace amine-associated receptor 1 (TAAR1 agonist)

PHARMACEUTICAL COMBINATION

The present invention relates to a pharmaceutical combination for the treatment of schizophrenia and acute manic episodes associated with bipolar disorders, which comprises a compound which is active on a trace amine-associated receptor 1 (TAAR1 agonist)